Deutsche Bank AG assumed coverage on shares of Innoviva, Inc. (NASDAQ:INVA) in a report issued on Monday, MarketBeat Ratings reports. The firm issued a hold rating and a $13.00 price target on the biotechnology company’s stock.

A number of other research analysts have also issued reports on INVA. Robert W. Baird reiterated a neutral rating and set a $13.00 price target (up previously from $11.00) on shares of Innoviva in a research report on Thursday, July 27th. Stifel Nicolaus reiterated a hold rating and set a $15.00 price target on shares of Innoviva in a research report on Friday, July 28th. Cowen Inc set a $16.00 price target on Innoviva and gave the stock a buy rating in a research report on Friday, July 28th. Zacks Investment Research upgraded Innoviva from a hold rating to a strong-buy rating and set a $16.00 price target for the company in a research report on Monday, July 31st. Finally, ValuEngine lowered Innoviva from a buy rating to a hold rating in a research report on Friday, September 1st. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company. Innoviva currently has an average rating of Hold and a consensus target price of $13.50.

Innoviva (INVA) opened at $13.42 on Monday. The company has a debt-to-equity ratio of -2.59, a quick ratio of 6.71 and a current ratio of 6.71. Innoviva has a 12-month low of $10.07 and a 12-month high of $14.87. The stock has a market capitalization of $1,448.48, a price-to-earnings ratio of 15.41 and a beta of 2.51.

Innoviva (NASDAQ:INVA) last announced its quarterly earnings results on Wednesday, October 25th. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.34 by ($0.13). Innoviva had a negative return on equity of 33.55% and a net margin of 52.91%. The business had revenue of $48.64 million for the quarter, compared to analyst estimates of $57.18 million. During the same quarter last year, the firm posted $0.13 EPS. The company’s revenue was up 46.0% compared to the same quarter last year. sell-side analysts expect that Innoviva will post 1.08 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Deutsche Bank AG Initiates Coverage on Innoviva, Inc. (INVA)” was originally published by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this story can be accessed at https://www.watchlistnews.com/deutsche-bank-ag-initiates-coverage-on-innoviva-inc-inva/1722871.html.

In other news, CFO Eric Desparbes sold 15,285 shares of the company’s stock in a transaction on Tuesday, November 21st. The stock was sold at an average price of $13.28, for a total value of $202,984.80. Following the completion of the sale, the chief financial officer now owns 337,027 shares in the company, valued at $4,475,718.56. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP George B. Abercrombie sold 5,215 shares of the company’s stock in a transaction on Tuesday, November 21st. The shares were sold at an average price of $13.26, for a total value of $69,150.90. Following the completion of the sale, the vice president now owns 263,866 shares of the company’s stock, valued at approximately $3,498,863.16. The disclosure for this sale can be found here. Corporate insiders own 1.60% of the company’s stock.

Several institutional investors have recently made changes to their positions in the company. GSA Capital Partners LLP acquired a new stake in shares of Innoviva in the third quarter valued at $1,111,000. Cubist Systematic Strategies LLC lifted its holdings in shares of Innoviva by 162.1% during the third quarter. Cubist Systematic Strategies LLC now owns 34,087 shares of the biotechnology company’s stock valued at $481,000 after purchasing an additional 21,082 shares during the last quarter. Sarissa Capital Management LP lifted its holdings in shares of Innoviva by 3.2% during the third quarter. Sarissa Capital Management LP now owns 3,600,705 shares of the biotechnology company’s stock valued at $50,841,000 after purchasing an additional 110,000 shares during the last quarter. Jane Street Group LLC purchased a new stake in shares of Innoviva during the third quarter valued at $144,000. Finally, Magnetar Financial LLC purchased a new stake in shares of Innoviva during the third quarter valued at $182,000. Institutional investors and hedge funds own 72.14% of the company’s stock.

Innoviva Company Profile

Innoviva, Inc, formerly Theravance, Inc, is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)).

Analyst Recommendations for Innoviva (NASDAQ:INVA)

Receive News & Ratings for Innoviva Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innoviva Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.